Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease

Silvia Campo, Brunilde Arseni, Stefania Rossi, Valeria D'Alessio, Ruying Lu, Joel Ngoje, Patrick L. Ahl, Susan Bonitz, Raphael Mannino, Diletta Di Mitri, Luca Battistini, Paolo Carminati, Rita De Santis, Vito Ruggiero

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We have previously demonstrated that the compound 3-(2-ethylphenyl)-5-(3- methoxyphenyl)-1H-1,2,4-triazole exerts immunosuppressive effects in several experimental models of autoimmunity. These results were achieved by subcutaneously administering ST1959 after dissolution in an oily vehicle, because of its poor water solubility. To circumvent this problem, we sought to determine whether nanocochleate technology could be successfully exploited to deliver ST1959 and protect mice undergoing lethal acute graft-versus-host disease (GVHD). Orally-administered encochleated ST1959 significantly protected animals from lethality, resulting in survival rates of 57% and 100% at doses of 2 and 10 mg/kg, respectively, whereas oral administration of 2 mg/kg ST1959, mixed with empty nanocochleates, was completely inactive. Increased survival was associated with diminished serum chemokine levels and donor CD8 T cells in the spleen of ST1959-treated mice. Moreover, ST1959 treatment significantly counteracted GVHD-induced normocitic anemia by increasing hemoglobin, hematocrit, platelet, and red and white blood cell counts. Overall, these data show that orally-administered encochleated ST1959 significantly protects mice from GVHD.

Original languageEnglish
Pages (from-to)171-175
Number of pages5
JournalTransplantation
Volume86
Issue number1
DOIs
Publication statusPublished - Jul 15 2008

Fingerprint

Triazoles
Graft vs Host Disease
Erythrocyte Count
3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole
Immunosuppressive Agents
Autoimmunity
Leukocyte Count
Hematocrit
Chemokines
Solubility
Oral Administration
Anemia
Hemoglobins
Theoretical Models
Blood Platelets
Spleen
Technology
T-Lymphocytes
Water
Serum

Keywords

  • CD62L
  • Chemokines
  • Graft-versus-host disease
  • ST1959 3 5-Diaryl-s-triazole

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease. / Campo, Silvia; Arseni, Brunilde; Rossi, Stefania; D'Alessio, Valeria; Lu, Ruying; Ngoje, Joel; Ahl, Patrick L.; Bonitz, Susan; Mannino, Raphael; Di Mitri, Diletta; Battistini, Luca; Carminati, Paolo; De Santis, Rita; Ruggiero, Vito.

In: Transplantation, Vol. 86, No. 1, 15.07.2008, p. 171-175.

Research output: Contribution to journalArticle

Campo, S, Arseni, B, Rossi, S, D'Alessio, V, Lu, R, Ngoje, J, Ahl, PL, Bonitz, S, Mannino, R, Di Mitri, D, Battistini, L, Carminati, P, De Santis, R & Ruggiero, V 2008, 'Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease', Transplantation, vol. 86, no. 1, pp. 171-175. https://doi.org/10.1097/TP.0b013e31817ba761
Campo, Silvia ; Arseni, Brunilde ; Rossi, Stefania ; D'Alessio, Valeria ; Lu, Ruying ; Ngoje, Joel ; Ahl, Patrick L. ; Bonitz, Susan ; Mannino, Raphael ; Di Mitri, Diletta ; Battistini, Luca ; Carminati, Paolo ; De Santis, Rita ; Ruggiero, Vito. / Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease. In: Transplantation. 2008 ; Vol. 86, No. 1. pp. 171-175.
@article{68a7a901499a4198944b053816a77c7c,
title = "Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease",
abstract = "We have previously demonstrated that the compound 3-(2-ethylphenyl)-5-(3- methoxyphenyl)-1H-1,2,4-triazole exerts immunosuppressive effects in several experimental models of autoimmunity. These results were achieved by subcutaneously administering ST1959 after dissolution in an oily vehicle, because of its poor water solubility. To circumvent this problem, we sought to determine whether nanocochleate technology could be successfully exploited to deliver ST1959 and protect mice undergoing lethal acute graft-versus-host disease (GVHD). Orally-administered encochleated ST1959 significantly protected animals from lethality, resulting in survival rates of 57{\%} and 100{\%} at doses of 2 and 10 mg/kg, respectively, whereas oral administration of 2 mg/kg ST1959, mixed with empty nanocochleates, was completely inactive. Increased survival was associated with diminished serum chemokine levels and donor CD8 T cells in the spleen of ST1959-treated mice. Moreover, ST1959 treatment significantly counteracted GVHD-induced normocitic anemia by increasing hemoglobin, hematocrit, platelet, and red and white blood cell counts. Overall, these data show that orally-administered encochleated ST1959 significantly protects mice from GVHD.",
keywords = "CD62L, Chemokines, Graft-versus-host disease, ST1959 3 5-Diaryl-s-triazole",
author = "Silvia Campo and Brunilde Arseni and Stefania Rossi and Valeria D'Alessio and Ruying Lu and Joel Ngoje and Ahl, {Patrick L.} and Susan Bonitz and Raphael Mannino and {Di Mitri}, Diletta and Luca Battistini and Paolo Carminati and {De Santis}, Rita and Vito Ruggiero",
year = "2008",
month = "7",
day = "15",
doi = "10.1097/TP.0b013e31817ba761",
language = "English",
volume = "86",
pages = "171--175",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease

AU - Campo, Silvia

AU - Arseni, Brunilde

AU - Rossi, Stefania

AU - D'Alessio, Valeria

AU - Lu, Ruying

AU - Ngoje, Joel

AU - Ahl, Patrick L.

AU - Bonitz, Susan

AU - Mannino, Raphael

AU - Di Mitri, Diletta

AU - Battistini, Luca

AU - Carminati, Paolo

AU - De Santis, Rita

AU - Ruggiero, Vito

PY - 2008/7/15

Y1 - 2008/7/15

N2 - We have previously demonstrated that the compound 3-(2-ethylphenyl)-5-(3- methoxyphenyl)-1H-1,2,4-triazole exerts immunosuppressive effects in several experimental models of autoimmunity. These results were achieved by subcutaneously administering ST1959 after dissolution in an oily vehicle, because of its poor water solubility. To circumvent this problem, we sought to determine whether nanocochleate technology could be successfully exploited to deliver ST1959 and protect mice undergoing lethal acute graft-versus-host disease (GVHD). Orally-administered encochleated ST1959 significantly protected animals from lethality, resulting in survival rates of 57% and 100% at doses of 2 and 10 mg/kg, respectively, whereas oral administration of 2 mg/kg ST1959, mixed with empty nanocochleates, was completely inactive. Increased survival was associated with diminished serum chemokine levels and donor CD8 T cells in the spleen of ST1959-treated mice. Moreover, ST1959 treatment significantly counteracted GVHD-induced normocitic anemia by increasing hemoglobin, hematocrit, platelet, and red and white blood cell counts. Overall, these data show that orally-administered encochleated ST1959 significantly protects mice from GVHD.

AB - We have previously demonstrated that the compound 3-(2-ethylphenyl)-5-(3- methoxyphenyl)-1H-1,2,4-triazole exerts immunosuppressive effects in several experimental models of autoimmunity. These results were achieved by subcutaneously administering ST1959 after dissolution in an oily vehicle, because of its poor water solubility. To circumvent this problem, we sought to determine whether nanocochleate technology could be successfully exploited to deliver ST1959 and protect mice undergoing lethal acute graft-versus-host disease (GVHD). Orally-administered encochleated ST1959 significantly protected animals from lethality, resulting in survival rates of 57% and 100% at doses of 2 and 10 mg/kg, respectively, whereas oral administration of 2 mg/kg ST1959, mixed with empty nanocochleates, was completely inactive. Increased survival was associated with diminished serum chemokine levels and donor CD8 T cells in the spleen of ST1959-treated mice. Moreover, ST1959 treatment significantly counteracted GVHD-induced normocitic anemia by increasing hemoglobin, hematocrit, platelet, and red and white blood cell counts. Overall, these data show that orally-administered encochleated ST1959 significantly protects mice from GVHD.

KW - CD62L

KW - Chemokines

KW - Graft-versus-host disease

KW - ST1959 3 5-Diaryl-s-triazole

UR - http://www.scopus.com/inward/record.url?scp=49849104757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849104757&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31817ba761

DO - 10.1097/TP.0b013e31817ba761

M3 - Article

VL - 86

SP - 171

EP - 175

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -